SCHEMBL7587012

SCHEMBL7587012

NC(=O)c1c(Cl)c(-c2cccnc2)n2ccccc12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MKNK1 Q9BUB5 8/20 0.46
MKNK2 Q9HBH9 7/20 0.46
RAD51 Q06609 1/20 0.43
MAP2K3 P46734 1/20 0.41
KDM4E B2RXH2 1/20 0.41
MEN1 O00255 1/20 0.41
ALDH1A1 P00352 1/20 0.41
MAPT P10636 1/20 0.41
MAPK1 P28482 1/20 0.41
PPARG P37231 1/20 0.41
KMT2A Q03164 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
NR2E3 Q9Y5X4 1/20 0.41
NCOR2 Q9Y618 1/20 0.41
CYP11B2 P19099 2/20 0.39
F7 P08709 1/20 0.38
F3 P13726 1/20 0.38
SARM1 Q6SZW1 1/20 0.38
SIRT2 Q8IXJ6 1/20 0.38
SIRT6 Q8N6T7 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7586180 0.85 MKNK1 (0.44) MKNK1MKNK2MAPTCYP11B2CYP11B1
SCHEMBL7584938 0.85 CYP11B2 (0.47) MKNK1MKNK2RAD51MAP2K3CYP11B2
SCHEMBL7589148 0.83 CYP11B2 (0.48) MKNK1MKNK2RAD51MAP2K3KDM4E
SCHEMBL7586224 0.82 MAP2K3 (0.37) MKNK1MKNK2MAP2K3KDM4EMEN1
SCHEMBL7588130 0.81 MKNK1 (0.46) MKNK1MKNK2RAD51MAPTCYP11B2
SCHEMBL7855338 0.76 CYP11B2 (0.48) MKNK1MKNK2RAD51KDM4EMEN1
SCHEMBL7585453 0.75 CYP11B2 (0.53) RAD51KDM4EALDH1A1KMT2ACYP11B2
SCHEMBL7586850 0.73 MAPT (0.52) KDM4EMEN1ALDH1A1MAPTMAPK1
Methane SCHEMBL7588227 0.72 MAPT (0.51) KDM4EMEN1ALDH1A1MAPTMAPK1
SCHEMBL7587040 0.72 MKNK1 (0.58) MKNK1MKNK2RAD51MAP2K3KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020006380-A1 Pyrrole derivatives, their preparation and pharmaceutical compositions containing them MIGNANI SERGE (FR) 2002-01-17 US claimed
EP-1086100-A1 PYRROLE DERIVATIVES, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME Aventis Pharma S.A. (FR) 2001-03-28 EP claimed
WO-1999064419-A1 PYRROLE DERIVATIVES, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AVENTIS PHARMA S.A. (FR) 1999-12-16 WO claimed
US-20020006380-A1 Pyrrole derivatives, their preparation and pharmaceutical compositions containing them MIGNANI SERGE (FR) 2002-01-17 US disclosed
EP-1086100-A1 PYRROLE DERIVATIVES, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME Aventis Pharma S.A. (FR) 2001-03-28 EP disclosed
WO-1999064419-A1 PYRROLE DERIVATIVES, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AVENTIS PHARMA S.A. (FR) 1999-12-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020006380-A1 Pyrrole derivatives, their preparation and pharmaceutical compositions containing them TNF, IL2, ZC3HAV1 MKNK1 4073/4885MKNK2 4131/4885RAD51 3727/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.